or Try an Advanced Search...

    Technical Analysis for COGT - Cogent Biosciences, Inc.

    Grade Last Price % Change Price Change
    D 9.08 0.22% 0.02
    COGT closed up 0.22 percent on Wednesday, November 20, 2024, on 1.69 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Down
    Historical COGT trend table...
    Date Alert Name Type % Chg
    Pocket Pivot Bullish Swing Setup 0.00%
    Wide Bands Range Expansion 0.00%
    Up 3 Days in a Row Strength 0.00%
    Oversold Stochastic Weakness 0.00%
    NR7 Range Contraction 0.22%
    Wide Bands Range Expansion 0.22%
    Oversold Stochastic Weakness 0.22%
    200 DMA Support Bullish 1.00%
    Lower Bollinger Band Walk Weakness 1.00%
    Wide Bands Range Expansion 1.00%
    Older End-of-Day Signals for COGT ...

       Recent Intraday Alerts

    Alert Time
    Possible Pocket Pivot about 16 hours ago
    Up 2% about 19 hours ago
    Rose Above Previous Day's High about 22 hours ago
    Up 1% about 22 hours ago
    Down 1% about 22 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    COGT Chart by TradingView
    Basic chart:

    Profile

    Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. Cogent's most advanced program, PLX9486, is a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Cogent is headquartered in Cambridge, MA.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Clinical Medicine Disease Gastrointestinal Enzymes Protein Kinase Inhibitor Tyrosine Kinase Imatinib Mastocytosis Systemic Mastocytosis Gastrointestinal Stromal Tumor

    Is COGT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 12 Cogent Biosciences GAAP EPS of -$0.64 misses by $0.08
    Nov 5 Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting
    Oct 23 Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics
    Oct 20 Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
    Oct 9 Analysts Rate Cogent Biosciences, Inc. (COGT) as Moderate Buy with $15 Target
    Sep 30 Cogent Biosciences: Need To Wait For More Data For Adequate Differentiation
    Sep 3 Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis
    Aug 6 Cogent Biosciences GAAP EPS of -$0.59
    Aug 6 Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results
    Jun 27 Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT trial
    See more COGT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 12.61
    52 Week Low 3.67
    Average Volume 1,144,739
    200-Day Moving Average 8.79
    50-Day Moving Average 10.89
    20-Day Moving Average 10.63
    10-Day Moving Average 9.71
    Average True Range 0.66
    RSI (14) 31.97
    ADX 34.16
    +DI 15.12
    -DI 34.56
    Chandelier Exit (Long, 3 ATRs) 10.62
    Chandelier Exit (Short, 3 ATRs) 10.55
    Upper Bollinger Bands 12.87
    Lower Bollinger Band 8.38
    Percent B (%b) 0.16
    BandWidth 42.21
    MACD Line -0.58
    MACD Signal Line -0.36
    MACD Histogram -0.2216
    Fundamentals Value
    Market Cap 782.01 Million
    Num Shares 86.1 Million
    EPS -2.34
    Price-to-Earnings (P/E) Ratio -3.88
    Price-to-Sales 1320.63
    Price-to-Book 3.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 9.64
    Resistance 3 (R3) 9.65 9.47 9.54
    Resistance 2 (R2) 9.47 9.33 9.47 9.51
    Resistance 1 (R1) 9.28 9.24 9.38 9.27 9.48
    Pivot Point 9.10 9.10 9.15 9.10 9.10
    Support 1 (S1) 8.91 8.96 9.01 8.90 8.68
    Support 2 (S2) 8.73 8.87 8.73 8.65
    Support 3 (S3) 8.54 8.73 8.62
    Support 4 (S4) 8.53